跳至主要内容
临床试验/CTRI/2022/05/042917
CTRI/2022/05/042917尚未招募未知

inear Clinical Study to Evaluate the Anti-Inflammatory and Beneficial Effects ofβ-1, 3-1, 6-Glucan, N-163 on another Muscular Dystrophy other than DMD Patients - N-163

MediNippon Health Care Private Limited MD0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1. Subject who diagnosed with another muscular dystrophy other than Duchenne Muscular Dystrophy (DMD)
  • 2. Male and Female subjects of age in between 3 years to 70 years
  • 3. Subjects and legally authorized representative for vulnerable subjects must be willing to participate in the study and provide a written informed consent
  • 4. Subject willing to and able to comply with the protocol

排除标准

  • 1. Subject participated in another clinical trial in the last 30 days.
  • 2. Subjects and legally authorized representative for vulnerable subjects who has not given informed consent for this study
  • 3. Subjects with history of multiple sclerosis
  • 4. Subjects with history of any muscular atrophy
  • 5. Pregnant and lactating females

研究者

发起方
MediNippon Health Care Private Limited MD

相似试验